PHARMA CLINICAL RESEARCH
Fast-Track Your Early-Stage Trials
Advance your Phase 1 study with a clinical research partner that meets your time requirements (without overspending).
When timelines slip, everything slows down.
For Pharma companies, every delay in early development costs more than just money—it risks market opportunities, disrupts pipelines, and strains internal resources.
You need a clinical research partner that keeps studies moving without inflating costs so you can avoid:
- Missed Market Opportunities — Every delay in early-phase research slows your path to commercialization and weakens competitive advantage.
- Pipeline Disruptions — Setbacks in one study can cascade across your development programs, creating costly bottlenecks.
- Resource Strains — Internal teams spend more time managing issues and less time advancing science when studies don’t stay on track.
A CRO Partner
Focused on Scientific Expertise
Clinical research organization delivering speed, precision, and cost-effective early-phase studies for Pharma.
As a trusted clinical research organization (CRO) serving more than 150 global companies, Axis brings vast experience in conducting phase studies for the last 110+ years, across a wide spectrum of studies, designed to meet Pharma’s most pressing needs:
- Pharmacology - SAD / MAD, DDI, PK/PD
- First-in-Human (FIH) Studies
- Cardiac Safety Studies
- dOMF Studies
- Bioanalytical Services
On Schedule & Within Budget
Rapid Timelines
Dedicated clinical trial units that accelerate study start-up and recruitment.
Efficient Execution
Proven strategies to control costs without sacrificing speed.
Reliable Data
Submission-ready results you and regulators can trust.
Pharma companies need a clinical research partner that can deliver speed and precision—without runaway costs. At Axis, we design every early-stage study to meet strict timelines, align with regulatory expectations, and deliver submission-ready data you can trust.
With a dedicated clinical research center, integrated bioanalytical services, and expert teams, we’re designed to help you move forward faster—without overspending or sacrificing data quality.
A Clinical Research Center Pharma Companies Trust
Fast-Track Your Early-Phase Clinical Trials
Pharmacology Services
From SAD/MAD to DDI and PK/PD studies, our clinical trial unit delivers the precision, speed, and submission-ready data that Pharma companies need to advance early-stage drug development.
Dermatology Studies
Whether vasoconstrictor, adhesion, irritation, or sensitization studies, Axis provides specialized dermatology clinical trials backed by rapid recruitment and advanced methods like dOFM.
hADME Studies
Axis conducts human ADME studies with precision and efficiency, generating critical insight into absorption, distribution, metabolism, and excretion to support global submissions.
dOFM Studies
Dermal Open Flow Microperfusion (dOFM) delivers deeper PK/PD insights from fewer subjects, helping Pharma companies move faster with data-driven dermatology development decisions.
Early TQT Studies / Cardiac Safety
Our TQT studies and ECG clinical trials ensure thorough cardiac safety assessments, with real-time cardiovascular monitoring and high-quality data for confident regulatory submissions.
A Clinical Trial Unit Trusted
By Biotech Innovators
A CLINICAL TRIAL UNIT
Built for Speed and Scale
Advancing clinical research with one of the largest Phase I clinical trial units in the U.S.
At the center of Axis is our state-of-the-art clinical research facility in Minnesota—one of the largest dedicated Phase I units in the U.S. Designed specifically for early-stage studies, our site combines capacity, expertise, and efficiency to keep your development moving forward.
- 200+ Dedicated Beds — Supporting both healthy volunteer and patient trials at scale.
- Integrated Bioanalytical Services — Lab and clinic in one location for faster turnaround and reduced costs.
- Experienced Clinical Research Specialists — A team that manages every detail with precision, ensuring quality and compliance from start to finish.
Axis delivers the speed, accuracy, and efficiency Pharma companies need to advance development while keeping costs under control.
Why Pharma Companies Partner with Axis
Pharma leaders choose Axis because we deliver the speed, efficiency, and quality needed to keep early-stage development moving—without inflating costs or compromising accuracy.
Axis is an end-to-end clinical research center designed for reliable data and accelerated timelines.
High-Enrolling US Site
Rapid start-up and fast enrollment to keep your clinical trial moving forward on schedule.
Cost Control
Efficient processes and resource management help you meet budgets while advancing your study.
Regulatory-Ready Data
Submission-quality results that meet FDA and global standards, supporting confident decision-making.
Complete Services
From pharmacology to bioanalytical services, everything you need is in one place for seamless execution.
Stay Ahead of Deadlines, Stay Ahead of the Market
Partner with a clinical research center that delivers fast timelines and reliable results.
What Our Clients Say
Real results and strong relationships—straight from the teams we’ve worked alongside.
"AXIS has consistently delivered outstanding support as a Phase 1 site partner. Their ability to recruit and enroll subjects quickly and efficiently has been a key factor in keeping our timelines on track. The team is professional, responsive, and well-organized, ensuring the smooth execution of even the most complex pharmacology studies. We value their expertise and look forward to continued collaboration."
"We've worked with AXIS Clinicals USA on several Phase 1 studies, and their ability to quickly enroll subjects has been a huge advantage for us. They’re efficient, easy to work with, and always meet our timelines. Their team handles everything smoothly, which makes our job easier. We’re grateful for their support and look forward to working with them again."
"Partnering with AXIS has been a transformative experience for us. Their team deeply understands the complexities of pharmacology cardiac safety TQT projects and has been exceptionally responsive and proactive at every stage. What could have been a challenging process was made significantly smoother, with seamless coordination between clinical and bioanalysis under one roof, keeping timelines on track and delivering high-quality data."
"AXIS has been our long-time reliable partner for clinical research. Their team understands the challenges of developing 505(b)(2) products and has provided solid support throughout our clinical development program of studies. They’ve helped us stay on track and navigate a complex process with professionalism and quality data. I would recommend them to all of my industry contacts looking for a dependable CRO partner."
Your Path to Fast
Your Roadmap to Fast, Reliable Phase 1 Clinical Trials
Every successful program depends on a clear plan. Here’s how Axis keeps your clinical trial on schedule, on budget, and designed to meet regulatory expectations.
Schedule a
Consultation
Share your study details, goals, and
timelines with our experts.
Get a Custom Proposal
& Trial Timeline
Get a proposal that's clear, efficient, and
tailored to your program’s needs.
Advance to Phase II
Quickly with Confidence
Hit milestones on schedule and keep your pipeline moving
Have questions or need expert support? Our team is here to help—reach out and let’s move forward together.
Get In Touch
Axis Blogs
Partner with a clinical research center that delivers fast timelines and reliable results.
- BLOG
How Novel Drug Delivery Systems Are Challenging Traditional BE Study Design
Bioequivalence (BE) studies have long relied on well-established assumptions about how drugs are administered, absorbed, and measured in the body.
- BLOG
How Genetic Variability Is Being Accounted for in Bioequivalence and PK/PD Studies
As drug development becomes increasingly global, sponsors are paying closer attention to how genetic variability
- BLOG
The Role of Metabolomics and Biomarker Analysis in Early Phase Clinical Trials
The rise of metabolomics and biomarker analysis in early phase clinical trials is reshaping how development teams evaluate pharmacological activity, human variability, and early indicators of safety.